Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 7/20 | 0.48 |
| ▸ | MPO | P05164 | 4/20 | 0.48 |
| ▸ | MGMT | P16455 | 7/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CDK1 | P06493 | 2/20 | 0.44 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.44 |
| ▸ | CDK2 | P24941 | 2/20 | 0.44 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | TPO | P07202 | 1/20 | 0.41 |
| ▸ | EPX | P11678 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20101702 | 0.88 | PIN1 (0.48) | PIN1MPOMGMTCYP3A4CDK1 | |
| SCHEMBL21160447 | 0.86 | PIN1 (0.47) | PIN1MPOMGMTCYP3A4CDK1 | |
| SCHEMBL15372394 | 0.86 | PIN1 (0.64) | PIN1MPOMGMTCYP3A4CDK1 | |
| SCHEMBL21036999 | 0.86 | PIN1 (0.51) | PIN1MPOMGMTCYP3A4CDK1 | |
| SCHEMBL3720508 | 0.84 | MGMT (0.52) | PIN1MPOMGMTCYP3A4CDK1 | |
| SCHEMBL12227592 | 0.84 | CDK1 (0.40) | PIN1CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL23764883 | 0.84 | PIN1 (0.49) | PIN1MPOMGMTCYP3A4CDK1 | |
| SCHEMBL1533391 | 0.83 | MPO (0.61) | PIN1MPOMGMTCYP3A4CDK1 | |
| 6-O-Benzylguanine SCHEMBL600698 | 0.83 | MGMT (0.63) | PIN1MPOMGMTCYP3A4CDK1 | |
| 6-O-Benzylguanine SCHEMBL29405347 | 0.83 | MGMT (0.63) | PIN1MPOMGMTCYP3A4CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10889616-B2 | Cytotoxic tubulysin compounds for conjugation | TUBE PHARMACEUTICALS GMBH (AT) | 2021-01-12 | — | — | US | disclosed |
| US-20190233471-A1 | CYTOTOXIC TUBULYSIN COMPOUNDS FOR CONJUGATION | TUBE PHARMACEUTICALS GMBH (AT) | 2019-08-01 | — | — | US | disclosed |
| US-10183970-B2 | Cytotoxic tubulysin compounds for conjugation | TUBE PHARMACEUTICALS GMBH (AT) | 2019-01-22 | — | — | US | disclosed |
| US-20160340386-A1 | CYTOTOXIC TUBULYSIN COMPOUNDS FOR CONJUGATION | TUBE PHARMACEUTICALS GMBH (AT) | 2016-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160340386-A1 | CYTOTOXIC TUBULYSIN COMPOUNDS FOR CONJUGATION | NGLY1, TEKT1, TWF2 | PIN1 3789/4885MPO 1263/4885MGMT 3012/4885 |
| US-20190233471-A1 | CYTOTOXIC TUBULYSIN COMPOUNDS FOR CONJUGATION | NGLY1, TEKT1, TWF2 | PIN1 3789/4885MPO 1263/4885MGMT 3012/4885 |
| US-10889616-B2 | Cytotoxic tubulysin compounds for conjugation | NGLY1, TEKT1, TWF2 | PIN1 3789/4885MPO 1263/4885MGMT 3012/4885 |
| US-10183970-B2 | Cytotoxic tubulysin compounds for conjugation | NGLY1, TEKT1, TWF2 | PIN1 3789/4885MPO 1263/4885MGMT 3012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.